Ongoing Surveillance of Infectious
Diseases
in Rheumatology–
A Case-based Discussion
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date:
August 4, 2011
Expiration Date:
August 4, 2012
Estimated Time of Completion: 30 minutes
Description
The purpose of this activity is to review the prevention and management of infectious diseases and their complications in rheumatic patients receiving immunosuppressant therapy.
Learning Objectives
On completion of this educational activity, participants will be able to:
- Implement appropriate measures of monitoring for potential adverse events in recognition of the potential consequences of immunosuppression.
- Outline clinical situations when therapy discontinuation or interruption may be required due to adverse events.
- Interpret the latest safety data on available and emerging DMARDs.
Target Audience
This activity is intended for rheumatologists and other healthcare professionals who manage and treat patients with RA.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman,
Department of Rheumatic and Immunologic Diseases
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Cleveland Clinic
Cleveland, Ohio
Faculty
Susan Rehm, MD |
|
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have relationships which, in the context of his presentation, could be perceived as a potential conflict of interest:
Leonard H. Calabrese, DO |
||
| Abbott Laboratories | Consulting | |
| Amgen Inc. | Consulting, Teaching and Speaking | |
| Bristol-Myers Squibb Company | Consulting, Teaching and Speaking | |
| Centocor, Inc. | Consulting, Teaching and Speaking | |
| Genentech, Inc. | Consulting, Teaching and Speaking | |
| Pfizer Inc. | Consulting | |
| Roche Laboratories, Inc. | Consulting | |
Susan Rehm, MD |
||
| Genentech, Inc. | Teaching and Speaking | |
| Merck & Co., Inc. | Membership on advisory committee or review panels | |
| Pfizer Inc. | Membership on advisory committee or review panels | |
| sanofi-aventis Group | Membership on advisory committee or review panels | |
All other planners, CME staff, and content reviewers, have no relevant financial relationships to disclose.
The Cleveland Clinic Foundation Center for Continuing Education acknowledges
an educational grant for support of this activity from:
Genentech, Inc.
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and
